Stockreport

FDA approves study of Alpha Tau's Alpha DaRT for recurrent cSCC treatment [Yahoo! Finance]

Alpha Tau Medical Ltd. - Ordinary Shares  (DRTS) 
PDF Secondary efficacy objectives of the Alpha DaRT cancer therapy study will focus on progression-free survival, overall survival, and local control up to 12 months post-t [Read more]